For the quarter ending 2025-09-30, BBNX had $3,410K increase in cash & cash equivalents over the period. -$10,011K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -14,209 | -45,525 |
| Depreciation expense | 385 | 650 |
| Provision for expected credit losses | 24 | 0 |
| Provision for net realizable value of inventory | - | 158 |
| Stock-based compensation expense | 4,478 | 7,603 |
| Net provision for excess and obsolete inventory | 435 | 189 |
| Change in fair value of warrant liabilities | 0 | 12,450 |
| Accretion of discount on short-term investments | -316 | -1,709 |
| Accretion of discount on long-term investments | 17 | -21 |
| Amortization of operating lease right-of-use asset | 298 | 607 |
| Accounts receivable | 168 | -601 |
| Inventories | 3,327 | 4,350 |
| Prepaid expenses and other current assets | 1,790 | 3,605 |
| Other long-term assets | 39 | -6 |
| Accounts payable | 1,100 | 471 |
| Accrued expenses and other current liabilities | 4,115 | -2,550 |
| Other long-term liabilities | 194 | 1,011 |
| Operating lease liability | -285 | -567 |
| Deferred revenue | 517 | 1,012 |
| Net cash used in operating activities | -8,729 | -33,569 |
| Purchases of short-term investments | 46,004 | 190,768 |
| Purchases of long-term investments | 14,228 | 31,069 |
| Proceeds from maturities and redemptions of short-term investments | 71,000 | 51,000 |
| Purchases of property and equipment | 1,282 | 2,112 |
| Net cash (used in) provided by investing activities | 9,486 | -172,949 |
| Proceeds from the issuance of common stock, net of underwriting discounts, commissions and issuance costs | 0 | 195,430 |
| Proceeds from the issuance of common stock from private placement, net of issuance costs | 0 | 15,591 |
| Proceeds from stock option exercises | 2,653 | 140 |
| Net cash provided by financing activities | 2,653 | 211,161 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 3,410 | 4,643 |
| Cash and cash equivalents at beginning of period | 30,532 | - |
| Cash and cash equivalents at end of period | 38,585 | - |
Beta Bionics, Inc. (BBNX)
Beta Bionics, Inc. (BBNX)